**UNITED      STATES SECURITIES AND EXCHANGE COMMISSION**

**FORM      10-QSB**

** QUARTERLY      REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE**

**ACT      OF 1934**

** TRANSITION      REPORT PURSUANT TO SECTION 13 0R 15(D) OF THE SECURITIES EXCHANGE**

**ACT      OF 1934**

*Commission      File Number: 000-51497*

 

**BIO-BRIDGE      SCIENCE, INC.**

| Delaware                                                |   | 20-1802936                         |
|---------------------------------------------------------|--------|------------------------------------|
| (State                or Other jurisdiction of          |   | (IRS                Employer       |
| incorporation                or organization)           |   | Identification                No.) |
|                                                    |   |                               |
| 1211                West 22nd Street, Suite 615         |   |                               |
| Oak                Brook, Illinois                      |   | 60523                              |
| (Address                of principal executive offices) |   | (Zip                Code)          |

----

**Bio-Bridge      Science, Inc**

|                   |   |                                                                                                                                                                                                                                                                                                             |   | Page  |
|------------------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------|
| Item                1. |   | Financial                Statements                                                                                                                                                                                                                                                                              |   | 3          |
|                   |   |                                                                                                                                                                                                                                                                                                             |   |       |
|                   |   | Condensed                Consolidated Balance Sheets as of September 30, 2007 (unaudited)                and December 31, 2006                                                                                                                                                                                   |   | 3          |
|                   |   |                                                                                                                                                                                                                                                                                                             |   |       |
|                   |   | Unaudited                Condensed Consolidated Statements of Operations for                the three and nine month periods ended September 30, 2007 and 2006                and                for                the period from February 11, 2002 (inception) through September 30,                2007 |   | 4          |
|                   |   |                                                                                                                                                                                                                                                                                                             |   |       |
|                   |   | Unaudited                Condensed Consolidated Statements of Changes in Shareholders' Equity                and                Comprehensive Gain (Loss) for the period from February 11, 2002                (inception) through                September 30, 2007                                             |   | 5          |
|                   |   |                                                                                                                                                                                                                                                                                                             |   |       |
|                   |   | Unaudited                Condensed Consolidated Statements of Cash Flows for                the nine month periods ended September 30, 2007 and 2006 and for                the period from February 11, 2002 (inception) through September 30,                2007                                              |   | 9          |
|                   |   |                                                                                                                                                                                                                                                                                                             |   |       |
|                   |   | Notes                to Unaudited Condensed Consolidated Financial Statements                                                                                                                                                                                                                                    |   | 10         |
|                   |   |                                                                                                                                                                                                                                                                                                             |   |       |
| Item                2. |   | Management's                Discussion and Analysis or Plan of Operation                                                                                                                                                                                                                                         |   | 19         |
|                   |   |                                                                                                                                                                                                                                                                                                             |   |       |
| Item                3. |   | Controls                and Procedures                                                                                                                                                                                                                                                                           |   | 24         |
|                   |   |                                                                                                                                                                                                                                                                                                             |   |       |
| Part                II |   | Other                Information                                                                                                                                                                                                                                                                                 |   | 24         |
|                   |   |                                                                                                                                                                                                                                                                                                             |   |       |
| Item                1. |   | Legal                Proceedings                                                                                                                                                                                                                                                                                 |   | 24         |
|                   |   |                                                                                                                                                                                                                                                                                                             |   |       |
| Item                2. |   | Unregistered                Sales of Equity Securities and Use of Proceeds                                                                                                                                                                                                                                       |   | 25         |
|                   |   |                                                                                                                                                                                                                                                                                                             |   |       |
| Item                3. |   | Defaults                Upon Senior Securities                                                                                                                                                                                                                                                                   |   | 25         |
|                   |   |                                                                                                                                                                                                                                                                                                             |   |       |
| Item                4. |   | Submission                of Matters to a Vote of Security Holders                                                                                                                                                                                                                                               |   | 25         |
|                   |   |                                                                                                                                                                                                                                                                                                             |   |       |
| Item                5. |   | Other                Information                                                                                                                                                                                                                                                                                 |   | 25         |
|                   |   |                                                                                                                                                                                                                                                                                                             |   |       |
| Item                6. |   | Exhibits                                                                                                                                                                                                                                                                                                         |   | 25         |
|                   |   |                                                                                                                                                                                                                                                                                                             |   |       |
|                   |   | SIGNATURES                                                                                                                                                                                                                                                                                                       |   | 25         |

----

 

**PART      I - FINANCIAL INFORMATION**

**Item      1. Financial Statements**

**BIO-BRIDGE      SCIENCE, INC. AND SUBSIDIARIES**

**(A      DEVELOPMENT STAGE COMPANY)**

**CONDENSED      CONSOLIDATED BALANCE SHEETS**

|                                                                                                                                                                                                                                          |   | **September                    30,****2007** |       | **December                    31,****2006** |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------------------------------------|------------|---------------------------------------------|--------|
|                                                                                                                                                                                                                                          |   | **(unaudited)**                         |       |                                        |   |
|  **ASSETS**                                                                                                                                                                                                                              |   |                                         |       |                                        |   |
| **CURRENT                    ASSETS**                                                                                                                                                                                                         |   |                                         |       |                                        |   |
| Cash                    and cash equivalents                                                                                                                                                                                                  |   | $                                            | 310,249    |                                        | $      | 149,613 |   |
|                                                                                                                                                                                                                                          |   |                                         |            |                                        |   |  |   |
| Prepaid                    expenses and other current assets                                                                                                                                                                                  |   |                                         | 20,283     |                                        |   | 16,828 |   |
|                                                                                                                                                                                                                                          |   |                                         |            |                                        |   |  |   |
| Marketable                    securities-trading                                                                                                                                                                                              |   |                                         | 1,669,254  |                                        |   | - |   |
|                                                                                                                                                                                                                                          |   |                                         |            |                                        |   |  |   |
| Note                    receivable                                                                                                                                                                                                            |   |                                         | 40,000     |                                        |   | 40,000 |   |
| Total                    current assets                                                                                                                                                                                                       |   |                                         | 2,039,786  |                                        |   | 206,441 |   |
|                                                                                                                                                                                                                                          |   |                                         |            |                                        |   |  |   |
| **FIXED                    ASSETS, NET**                                                                                                                                                                                                      |   |                                         | 66,352     |                                        |   | 76,238 |   |
|                                                                                                                                                                                                                                          |   |                                         |            |                                        |   |  |   |
| **CONSTRUCTION                    IN PROGRESS**                                                                                                                                                                                               |   |                                         | 1,757,824  |                                        |   | 1,674,104 |   |
|                                                                                                                                                                                                                                          |   |                                         |            |                                        |   |  |   |
| **LAND                    USE RIGHT**                                                                                                                                                                                                         |   |                                         | 360,880    |                                        |   | 359,658 |   |
|                                                                                                                                                                                                                                          |   |                                         |            |                                        |   |  |   |
| **TOTAL                    ASSETS**                                                                                                                                                                                                           |   | $                                            | 4,224,842  |                                        | $      | 2,316,441 |   |
|                                                                                                                                                                                                                                          |   |                                         |            |                                        |   |  |   |
| **LIABILITIES                    AND SHAREHOLDERS’ EQUITY**                                                                                                                                                                             |
|                                                                                                                                                                                                                                          |   |                                         |            |                                        |   |  |   |
| **CURRENT                    LIABILITIES**                                                                                                                                                                                                    |   |                                         |            |                                        |   |  |   |
| Accrued                    expenses and other payables                                                                                                                                                                                        |   | $                                            | 151,149    |                                        | $      | 155,444 |   |
| Amount                    due to shareholder                                                                                                                                                                                                  |   |                                         | -          |                                        |   | 18,885 |   |
| Payable                    to contractors                                                                                                                                                                                                     |   |                                         | 120,613    |                                        |   | 474,586 |   |
| Total                    current liabilities                                                                                                                                                                                                  |   |                                         | 271,762    |                                        |   | 648,915 |   |
|                                                                                                                                                                                                                                          |   |                                         |            |                                        |   |  |   |
| **COMMITMENTS                    AND CONTINGENCIES**                                                                                                                                                                                          |   |                                         |            |                                        |   |  |   |
|                                                                                                                                                                                                                                          |   |                                         |            |                                        |   |  |   |
| **SHAREHOLDERS’                    EQUITY**                                                                                                                                                                                             |   |                                         |            |                                        |   |  |   |
| Preferred                    stock, $0.001 par value, liquidation preference of $3,000,000,                    5,000,000                    shares authorized, 4,000,000 and 0 shares issued and outstanding,                    respectively |   |                                         | 4,000      |                                        |   | - |   |
| Common                    stock, $0.001 par value, 100,000,000 shares authorized, 34,177,676                    and                    33,492,001 shares issued and outstanding, respectively                                                 |   |                                         | 34,178     |                                        |   | 33,492 |   |
| Additional                    paid-in capital                                                                                                                                                                                                 |   |                                         | 10,505,402 |                                        |   | 5,469,402 |   |
| Preferred                    stock dividend payable in common shares                                                                                                                                                                          |   |                                         | 47,000     |                                        |   | - |   |
| Subscription                    receivable                                                                                                                                                                                                    |   |                                         | (200,020   | )                                           |   | (25,091 | ) |
| Common                    stock to be issued, 496,667 and 240,000 shares,                    respectively                                                                                                                                     |   |                                         | 497        |                                        |   | 240 |   |
| Accumulated                    other comprehensive gain                                                                                                                                                                                       |   |                                         | 159,571    |                                        |   | 80,403 |   |
| Deficit                    accumulated during the development stage                                                                                                                                                                           |   |                                         | (6,597,548 | )                                           |   | (3,890,920 | ) |
|                                                                                                                                                                                                                                          |   |                                         |            |                                        |   |  |   |
| Total                    Shareholders’ Equity                                                                                                                                                                                           |   |                                         | 3,953,080  |                                        |   | 1,667,526 |   |
|                                                                                                                                                                                                                                          |   |                                         |            |                                        |   |  |   |
| **TOTAL                    LIABILITIES AND SHAREHOLDERS’ EQUITY**                                                                                                                                                                       |   | $                                            | 4,224,842  |                                        | $      | 2,316,441 |   |

----

 

**BIO-BRIDGE      SCIENCE INC. AND SUBSIDIARIES**

**(A      DEVELOPMENT STAGE COMPANY)**

**UNAUDITED      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

|                                                                                                         |   | **Three****Months****Ended****September                  30,****2007** |       | **Three****Months****Ended**** September                  30,****2006** |   | **Nine                  Months****Ended****September                  30,****2007** |   | **Nine                  Months****Ended****September                  30,****2006** |       | **For                  the Period****from                  February****11,                  2002****(Inception)****through                  September 30,****2007** |   |
|--------------------------------------------------------------------------------------------------------------|--------|------------------------------------------------------------------------|------------|------------------------------------------------------------------------------|--------|-------------------------------------------------------------------------------------|--------|-------------------------------------------------------------------------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
|                                                                                                         |   |                                                                   |       |                                                                         |   |                                                                                |   |                                                                                |       |                                                                                                                                                                |   |
| **REVENUE**                                                                                                  |   | $                                                                      | 1,694      |                                                                         | $      | 733                                                                                 |   | $                                                                                   | 2,384      |                                                                                                                                                                | $      | 1,006 |   | $ | 4,152 |   |
| **COST                  OF GOODS SOLD**                                                                      |   |                                                                   | (950       | )                                                                            |   | (539                                                                                | )      |                                                                                | (1,355     | )                                                                                                                                                                   |   | (623 | ) |   | (2,534 | ) |
| **GROSS                  PROFIT**                                                                            |   |                                                                   | 744        |                                                                         |   | 194                                                                                 |   |                                                                                | 1,029      |                                                                                                                                                                |   | 383 |   |   | 1,618 |   |
|                                                                                                         |   |                                                                   |            |                                                                         |   |                                                                                     |   |                                                                                |            |                                                                                                                                                                |   |  |   |   |  |   |
| Research                  and development costs                                                              |   |                                                                   | (21,476    | )                                                                            |   | (22,401                                                                             | )      |                                                                                | (103,816   | )                                                                                                                                                                   |   | (72,845 | ) |   | (421,070 | ) |
| Selling                  and distribution expenses                                                           |   |                                                                   | (8,640     | )                                                                            |   | (6,786                                                                              | )      |                                                                                | (24,952    | )                                                                                                                                                                   |   | (13,430 | ) |   | (73,105 | ) |
| General                  and administrative expenses                                                         |   |                                                                   | (203,878   | )                                                                            |   | (279,544                                                                            | )      |                                                                                | (922,570   | )                                                                                                                                                                   |   | (970,104 | ) |   | (4,460,394 | ) |
|                                                                                                         |   |                                                                   |            |                                                                         |   |                                                                                     |   |                                                                                |            |                                                                                                                                                                |   |  |   |   |  |   |
| **LOSS                  FROM OPERATIONS**                                                                    |   |                                                                   | (233,250   | )                                                                            |   | (308,537                                                                            | )      |                                                                                | (1,050,309 | )                                                                                                                                                                   |   | (1,055,996 | ) |   | (4,952,951 | ) |
|                                                                                                         |   |                                                                   |       |                                                                         |   |                                                                                |   |                                                                                |       |                                                                                                                                                                |   |   |   |   |   |   |
| **INTEREST                  INCOME**                                                                         |   |                                                                   | 1,328      |                                                                         |   | 1,005                                                                               |   |                                                                                | 5,128      |                                                                                                                                                                |   | 3,012 |   |   | 16,850 |   |
|                                                                                                         |   |                                                                   |            |                                                                         |   |                                                                                     |   |                                                                                |            |                                                                                                                                                                |   |  |   |   |  |   |
| **UNREALIZED                  LOSS ON TRADING SECURITIES**                                                   |   |                                                                   | (119,504   | )                                                                            |   | -                                                                                   |   |                                                                                | (227,930   | )                                                                                                                                                                   |   | - |   |   | (227,930 | ) |
|                                                                                                         |   |                                                                   |            |                                                                         |   |                                                                                     |   |                                                                                |            |                                                                                                                                                                |   |  |   |   |  |   |
| **DIVIDEND                  INCOME**                                                                         |   |                                                                   | 38,801     |                                                                         |   | -                                                                                   |   |                                                                                | 86,803     |                                                                                                                                                                |   | - |   |   | 86,803 |   |
|                                                                                                         |   |                                                                   |            |                                                                         |   |                                                                                     |   |                                                                                |            |                                                                                                                                                                |   |  |   |   |  |   |
| **NET                  LOSS**                                                                                |   |                                                                   | (312,625   | )                                                                            |   | (307,532                                                                            | )      |                                                                                | (1,186,308 | )                                                                                                                                                                   |   | (1,052,984 | ) |   | (5,077,228 | ) |
|                                                                                                         |   |                                                                   |            |                                                                         |   |                                                                                     |   |                                                                                |            |                                                                                                                                                                |   |  |   |   |  |   |
| **DEEMED                  PREFERRED STOCK DIVIDEND**                                                         |   |                                                                   | -          |                                                                         |   | -                                                                                   |   |                                                                                | (1,293,320 | )                                                                                                                                                                   |   | - |   |   | (1,293,320 | ) |
|                                                                                                         |   |                                                                   |            |                                                                         |   |                                                                                     |   |                                                                                |            |                                                                                                                                                                |   |  |   |   |  |   |
| **PREFERRED                  STOCK DIVIDENDS**                                                               |   |                                                                   | (90,000    | )                                                                            |   | -                                                                                   |   |                                                                                | (227,000   | )                                                                                                                                                                   |   | - |   |   | (227,000 | ) |
|                                                                                                         |   |                                                                   |            |                                                                         |   |                                                                                     |   |                                                                                |            |                                                                                                                                                                |   |  |   |   |  |   |
| **NET                  LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS**                                            |   | $                                                                      | (402,625   | )                                                                            | $      | (307,532                                                                            | )      | $                                                                                   | (2,706,628 | )                                                                                                                                                                   | $      | (1,052,984 | ) | $ | (6,597,548 | ) |
|                                                                                                         |   |                                                                   |            |                                                                         |   |                                                                                     |   |                                                                                |            |                                                                                                                                                                |   |  |   |   |  |   |
| **LOSS                  PER SHARE, attributable to common shareholders, basic and                  diluted** |   | $                                                                      | (0.01      | )                                                                            | $      | (0.01                                                                               | )      | $                                                                                   | (0.08      | )                                                                                                                                                                   | $      | (0.03 | ) |   |  |   |
|                                                                                                         |   |                                                                   |            |                                                                         |   |                                                                                     |   |                                                                                |            |                                                                                                                                                                |   |  |   |   |  |   |
| **WEIGHTED                  AVERAGE SHARES OUTSTANDING, basic and diluted**                                  |   |                                                                   | 34,177,676 |                                                                         |   | 33,086,740                                                                          |   |                                                                                | 33,874,655 |                                                                                                                                                                |   | 32,823,786 |   |   |  |   |

----

 

**BIO-BRIDGE      SCIENCE INC. AND SUBSIDIARIES**

**(A      DEVELOPMENT STAGE COMPANY)**

**UNAUDITED      CONDENSED CONSOLIDATED STATEMENTS OF CHANGES**

**IN      SHAREHOLDERS’ EQUITY AND COMPREHENSIVE GAIN (LOSS) FOR THE PERIOD FROM FEBRUARY      11, 2002**

**(INCEPTION)      THROUGH SEPTEMBER 30, 2007**

|                                                                       |   |   |                                  |   |   |          |   |   | Additional     |   |   |                           |   |   | Common                    Stock  |   |   | AccumulatedOther                |   |   | DeficitAccumulatedDuring                    the  |   |   |        |   |
|----------------------------------------------------------------------------|--------|--------|---------------------------------------|--------|--------|---------------|--------|--------|----------------|--------|--------|--------------------------------|--------|--------|---------------------------------------|--------|--------|--------------------------------------|--------|--------|-------------------------------------------------------|--------|--------|-------------|--------|
|                                                                       |   |   | Common                    Stock  |   |   | Paid-in  |   |   | Deferred  |   |   | To                    be  |   |   | Comprehensive                    |   |   | Development                     |   |   |                                                  |   |
|                                                                       |   |   | Shares                           |   |   | Amount   |   |   | Capital   |   |   | Compensation              |   |   | Issued                           |   |   | Gain                    (Loss)  |   |   | Stage                                            |   |   | Total  |   |
| Issuance                    of 13,750,000 shares at $0.00004               |   |   | 13,750,000                            |   | $      | 13,750        |   | $      | (13,200        | )      | $      | -                              |   | $      | -                                     |   | $      | -                                    |   | $      | -                                                     |   | $      | 550         |   |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Issuance                    of 7,461,090 shares at $0.0468                 |   |   | 7,461,090                             |   |   | 7,461         |   |   | 341,719        |   |   | -                              |   |   | -                                     |   |   | -                                    |   |   | -                                                     |   |   | 349,180     |   |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Issuance                    of 1,875,000 shares at $0.12                   |   |   | 1,875,000                             |   |   | 1,875         |   |   | 223,125        |   |   | -                              |   |   | -                                     |   |   | -                                    |   |   | -                                                     |   |   | 225,000     |   |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Foreign                    currency translation loss                       |   |   | -                                     |   |   | -             |   |   | -              |   |   | -                              |   |   | -                                     |   |   | (499                                 | )      |   | -                                                     |   |   | (499        | )      |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Net                    loss                                                |   |   | -                                     |   |   | -             |   |   | -              |   |   | -                              |   |   | -                                     |   |   | -                                    |   |   | (114,476                                              | )      |   | (114,476    | )      |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| **BALANCE                    DECEMBER 31, 2002**                           |   |   | 23,086,090                            |   |   | 23,086        |   |   | 551,644        |   |   | -                              |   |   | -                                     |   |   | (499                                 | )      |   | (114,476                                              | )      |   | 459,755     |   |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Issuance                    of 3,508,425 shares at $0.12                   |   |   | 3,508,425                             |   |   | 3,509         |   |   | 417,502        |   |   | -                              |   |   | -                                     |   |   | -                                    |   |   | -                                                     |   |   | 421,011     |   |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Issuance                    of 201,200 shares at $0.32                     |   |   | 201,200                               |   |   | 201           |   |   | 64,186         |   |   | -                              |   |   | -                                     |   |   | -                                    |   |   | -                                                     |   |   | 64,387      |   |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Foreign                    currency translation loss                       |   |   | -                                     |   |   | -             |   |   | -              |   |   | -                              |   |   | -                                     |   |   | (644                                 | )      |   | -                                                     |   |   | (644        | )      |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Net                    loss                                                |   |   | -                                     |   |   | -             |   |   | -              |   |   | -                              |   |   | -                                     |   |   | -                                    |   |   | (255,020                                              | )      |   | (255,020    | )      |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| **BALANCE                    DECEMBER 31, 2003**                           |   |   | 26,795,715                            |   |   | 26,796        |   |   | 1,033,332      |   |   | -                              |   |   | -                                     |   |   | (1,143                               | )      |   | (369,496                                              | )      |   | 689,489     |   |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Issuance                    of 434,600 shares at $0.12                     |   |   | 434,600                               |   |   | 435           |   |   | 51,715         |   |   | -                              |   |   | -                                     |   |   | -                                    |   |   | -                                                     |   |   | 52,150      |   |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Issuance                    of 1,125,275 shares at $0.32                   |   |   | 1,125,275                             |   |   | 1,125         |   |   | 358,961        |   |   | -                              |   |   | -                                     |   |   | -                                    |   |   | -                                                     |   |   | 360,086     |   |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Issuance                    of 1,616,000 shares at $0.50                   |   |   | 1,616,000                             |   |   | 1,616         |   |   | 806,382        |   |   | -                              |   |   | -                                     |   |   | -                                    |   |   | -                                                     |   |   | 807,998     |   |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Fair                    market value of Stock options granted for services |   |   | -                                     |   |   | -             |   |   | 695,052        |   |   | -                              |   |   | -                                     |   |   | -                                    |   |   | -                                                     |   |   | 695,052     |   |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Fair                    value of shares issued for services                |   |   | 100,000                               |   |   | 100           |   |   | 49,900         |   |   | -                              |   |   | -                                     |   |   | -                                    |   |   | -                                                     |   |   | 50,000      |   |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Exercise                    of options                                     |   |   | 200,000                               |   |   | 200           |   |   | -              |   |   | -                              |   |   | -                                     |   |   | -                                    |   |   | -                                                     |   |   | 200         |   |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Deferred                    consulting expenses                            |   |   | -                                     |   |   | -             |   |   | -              |   |   | (390,890                       | )      |   | -                                     |   |   | -                                    |   |   | -                                                     |   |   | (390,890    | )      |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Foreign                    currency translation loss                       |   |   | -                                     |   |   | -             |   |   | -              |   |   | -                              |   |   | -                                     |   |   | (457                                 | )      |   | -                                                     |   |   | (457        | )      |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| Net                    loss                                                |   |   | -                                     |   |   | -             |   |   | -              |   |   | -                              |   |   | -                                     |   |   | -                                    |   |   | (944,437                                              | )      |   | (944,437    | )      |
|                                                                       |   |   |                                  |   |   |          |   |   |           |   |   |                           |   |   |                                  |   |   |                                 |   |   |                                                  |   |   |        |   |
| **BALANCE                    DECEMBER 31, 2004**                      |   |   | 30,271,590                            |   | $      | 30,272        |   | $      | 2,995,342      |   | $      | (390,890                       | )      | $      | -                                     |   | $      | (1,600                               | )      | $      | (1,313,933                                            | )      | $      | 1,319,191   |   |

----

 

**BIO-BRIDGE      SCIENCE INC. AND SUBSIDIARIES**

**(A      DEVELOPMENT STAGE COMPANY)**

**UNAUDITED      CONDENSED CONSOLIDATED STATEMENTS OF CHANGES**

**IN      SHAREHOLDERS’ EQUITY AND COMPREHENSIVE GAIN (LOSS) FOR THE PERIOD FROM FEBRUARY      11, 2002**

**(INCEPTION)      THROUGH SEPTEMBER 30, 2007 (Continued)**

|                                                                 |   |   |                                    |   |   |          |   |   | Additional  |   |   |                             |   |   | Common                      Stock  |   |   | Accumulated                       Other  |   |   | Deficit                       Accumulated During                      the  |   |   |        |   |
|----------------------------------------------------------------------|--------|--------|-----------------------------------------|--------|--------|---------------|--------|--------|------------------|--------|--------|----------------------------------|--------|--------|-----------------------------------------|--------|--------|----------------------------------------------------|--------|--------|-------------------------------------------------------------------------------------------|--------|--------|-------------|--------|
|                                                                 |   |   | Common                      Stock  |   |   | Paid-in  |   |   | Deferred    |   |   | To                      be  |   |   | Comprehensive                      |   |   | Development                                   |   |   |                                                                                      |   |
|                                                                 |   |   | Shares                             |   |   | Amount   |   |   | Capital     |   |   | Compensation                |   |   | Issued                             |   |   | Gain                      (Loss)              |   |   | Stage                                                                                |   |   | Total  |   |
| **BALANCE                      DECEMBER 31, 2004**                   |   |   | 30,271,590                              |   | $      | 30,272        |   | $      | 2,995,342        |   | $      | (390,890                         | )      | $      | -                                       |   | $      | (1,600                                             | )      | $      | (1,313,933                                                                                | )      | $      | 1,319,191   |   |
|                                                                 |   |   |                                    |   |   |          |   |   |             |   |   |                             |   |   |                                    |   |   |                                               |   |   |                                                                                      |   |   |        |   |
| Issuance                      of 2,179,947 shares at $0.50           |   |   | 2,179,947                               |   |   | 2,180         |   |   | 1,087,794        |   |   | -                                |   |   | -                                       |   |   | -                                                  |   |   | -                                                                                         |   |   | 1,089,974   |   |
|                                                                 |   |   |                                    |   |   |          |   |   |             |   |   |                             |   |   |                                    |   |   |                                               |   |   |                                                                                      |   |   |        |   |
| Stock                      options issued for services               |   |   | -                                       |   |   | -             |   |   | 34,935           |   |   | (34,935                          | )      |   | -                                       |   |   | -                                                  |   |   | -                                                                                         |   |   | -           |   |
|                                                                 |   |   |                                    |   |   |          |   |   |             |   |   |                             |   |   |                                    |   |   |                                               |   |   |                                                                                      |   |   |        |   |
| Stock                      options granted to employees and officers |   |   | -                                       |   |   | -             |   |   | 680,604          |   |   | (680,604                         | )      |   | -                                       |   |   | -                                                  |   |   | -                                                                                         |   |   | -           |   |
|                                                                 |   |   |                                    |   |   |          |   |   |             |   |   |                             |   |   |                                    |   |   |                                               |   |   |                                                                                      |   |   |        |   |
| Amortization                      of deferred compensation expenses  |   |   | -                                       |   |   | -             |   |   | -                |   |   | 458,127                          |   |   | -                                       |   |   | -                                                  |   |   | -                                                                                         |   |   | 458,127     |   |
|                                                                 |   |   |                                    |   |   |          |   |   |             |   |   |                             |   |   |                                    |   |   |                                               |   |   |                                                                                      |   |   |        |   |
| Return                      of options                               |   |   | -                                       |   |   | -             |   |   | (139,604         | )      |   | 139,604                          |   |   | -                                       |   |   | -                                                  |   |   | -                                                                                         |   |   | -           |   |
|                                                                 |   |   |                                    |   |   |          |   |   |             |   |   |                             |   |   |                                    |   |   |                                               |   |   |                                                                                      |   |   |        |   |
| Exercise                      of options                             |   |   | -                                       |   |   | -             |   |   | (328             | )      |   | -                                |   |   | 328                                     |   |   | -                                                  |   |   | -                                                                                         |   |   | -           |   |
|                                                                 |   |   |                                    |   |   |          |   |   |             |   |   |                             |   |   |                                    |   |   |                                               |   |   |                                                                                      |   |   |        |   |
| Foreign                      currency translation loss               |   |   | -                                       |   |   | -             |   |   | -                |   |   | -                                |   |   | -                                       |   |   | 26,882                                             |   |   | -                                                                                         |   |   | 26,882      |   |
|                                                                 |   |   |                                    |   |   |          |   |   |             |   |   |                             |   |   |                                    |   |   |                                               |   |   |                                                                                      |   |   |        |   |
| Net                      loss                                        |   |   | -                                       |   |   | -             |   |   | -                |   |   | -                                |   |   | -                                       |   |   | -                                                  |   |   | (1,253,093                                                                                | )      |   | (1,253,093  | )      |
| **BALANCE                      DECEMBER 31, 2005**                   |   |   | 32,451,537                              |   | $      | 32,452        |   | $      | 4,658,743        |   | $      | (508,698                         | )      | $      | 328                                     |   | $      | 25,282                                             |   | $      | (2,567,026                                                                                | )      | $      | 1,641,081   |   |

----

 

**BIO-BRIDGE      SCIENCE INC. AND SUBSIDIARIES**

**(A      DEVELOPMENT STAGE COMPANY)**

**UNAUDITED      CONDENSED CONSOLIDATED STATEMENTS OF CHANGES**

**IN      SHAREHOLDERS’ EQUITY AND COMPREHENSIVE GAIN (LOSS) FOR THE PERIOD FROM FEBRUARY      11, 2002**

**(INCEPTION)      THROUGH SEPTEMBER 30, 2007 (Continued)**

|                                                                                                                  |   |   |                                               |   |   |                      |   |   |                      Additional            |   |   |                                 |   |   |  Common                    Stock |   |   |                      AccumulatedOther    |   |   |                         |   |   |                       Deficit AccumulatedDuring                    the  |   |   |                    |   |
|-----------------------------------------------------------------------------------------------------------------------|--------|--------|----------------------------------------------------|--------|--------|---------------------------|--------|--------|------------------------------------------------------|--------|--------|--------------------------------------|--------|--------|---------------------------------------|--------|--------|--------------------------------------------------------------|--------|--------|------------------------------|--------|--------|----------------------------------------------------------------------------------------|--------|--------|-------------------------|--------|
|                                                                                                                  |   |   | Common                    Stock               |   |   | Paid-in    |   |   |                      Deferred    |   |   | To                    be   |   |   | Comprehensive                    |   |   |  Subscriptions                                |   |   |  Development       |   |   |                                                                                   |   |
|                                                                                                                  |   |   |                      Shares    |   |   | Amount          |   |   |                      Capital     |   |   |  Compensation         |   |   |   Issued               |   |   |  Gain                    (Loss)               |   |   | Receivable    |   |   |                      Stage                                         |   |   | Total    |   |
| **BALANCE                    DECEMBER 31, 2005**                                                                      |   |   | 32,451,537                                         |   | $      | 32,452                    |   | $      | 4,658,743                                            |   | $      | (508,698                             | )      | $      | 328                                   |   | $      | 25,282                                                       |   | $      | -                            |   | $      | (2,567,026                                                                             | )      | $      | 1,641,081               |   |
|                                                                                                                  |   |   |                                               |   |   |                      |   |   |                                                 |   |   |                                 |   |   |                                  |   |   |                                                         |   |   |                         |   |   |                                                                                   |   |   |                    |   |
| Reclassification                    of deferred compensation balance to                    additional-paid-in-capital |   |   | -                                                  |   |   | -                         |   |   | (508,698                                             | )      |   | 508,698                              |   |   | -                                     |   |   | -                                                            |   |   | -                            |   |   | -                                                                                      |   |   | -                       |   |
|                                                                                                                  |   |   |                                               |   |   |                      |   |   |                                                 |   |   |                                 |   |   |                                  |   |   |                                                         |   |   |                         |   |   |                                                                                   |   |   |                    |   |
| Issuance                    of shares for previously exercised stock options                                          |   |   | 328,116                                            |   |   | 328                       |   |   | -                                                    |   |   | -                                    |   |   | (328)                                 | )      |   | -                                                            |   |   | -                            |   |   | -                                                                                      |   |   | -                       |   |
|                                                                                                                  |   |   |                                               |   |   |                      |   |   |                                                 |   |   |                                 |   |   |                                  |   |   |                                                         |   |   |                         |   |   |                                                                                   |   |   |                    |   |
| Sales                    of shares at $0.75 to $1.20 per share for cash, net of issuance                    costs     |   |   | 540,348                                            |   |   | 540                       |   |   | 872,637                                              |   |   | -                                    |   |   | 240                                   |   |   | -                                                            |   |   | (25,091                      | )      |   | -                                                                                      |   |   | 848,326                 |   |
|                                                                                                                  |   |   |                                               |   |   |                      |   |   |                                                 |   |   |                                 |   |   |                                  |   |   |                                                         |   |   |                         |   |   |                                                                                   |   |   |                    |   |
| Compensatory                    shares issued to consultant                                                           |   |   | 122,000                                            |   |   | 122                       |   |   | 223,773                                              |   |   | -                                    |   |   | -                                     |   |   | -                                                            |   |   | -                            |   |   | -                                                                                      |   |   | 223,895                 |   |
|                                                                                                                  |   |   |                                               |   |   |                      |   |   |                                                 |   |   |                                 |   |   |                                  |   |   |                                                         |   |   |                         |   |   |                                                                                   |   |   |                    |   |
| Employee                    stock options                                                                             |   |   | -                                                  |   |   | -                         |   |   | 174,670                                              |   |   | -                                    |   |   | -                                     |   |   | -                                                            |   |   | -                            |   |   | -                                                                                      |   |   | 174,670                 |   |
|                                                                                                                  |   |   |                                               |   |   |                      |   |   |                                                 |   |   |                                 |   |   |                                  |   |   |                                                         |   |   |                         |   |   |                                                                                   |   |   |                    |   |
| Consultant                    stock options                                                                           |   |   | -                                                  |   |   | -                         |   |   | 48,277                                               |   |   | -                                    |   |   | -                                     |   |   | -                                                            |   |   | -                            |   |   | -                                                                                      |   |   | 48,277                  |   |
|                                                                                                                  |   |   |                                               |   |   |                      |   |   |                                                 |   |   |                                 |   |   |                                  |   |   |                                                         |   |   |                         |   |   |                                                                                   |   |   |                    |   |
| Exercise                    of options                                                                                |   |   | 50,000                                             |   |   | 50                        |   |   | -                                                    |   |   | -                                    |   |   | -                                     |   |   | -                                                            |   |   | -                            |   |   | -                                                                                      |   |   | 50                      |   |
|                                                                                                                  |   |   |                                               |   |   |                      |   |   |                                                 |   |   |                                 |   |   |                                  |   |   |                                                         |   |   |                         |   |   |                                                                                   |   |   |                    |   |
| Foreign                    currency translation loss                                                                  |   |   | -                                                  |   |   | -                         |   |   | -                                                    |   |   | -                                    |   |   |                                  |   |   | 55,121                                                       |   |   | -                            |   |   | -                                                                                      |   |   | 55,121                  |   |
|                                                                                                                  |   |   |                                               |   |   |                      |   |   |                                                 |   |   |                                 |   |   |                                  |   |   |                                                         |   |   |                         |   |   |                                                                                   |   |   |                    |   |
| Net                    loss                                                                                           |   |   | -                                                  |   |   | -                         |   |   | -                                                    |   |   | -                                    |   |   | -                                     |   |   | -                                                            |   |   | -                            |   |   | (1,323,894)                                                                            | )      |   | (1,323,894              | )      |
| **BALANCE                    DECEMBER 31, 2006**                                                                      |   |   | 33,492,001                                         |   | $      | 33,492                    |   | $      | 5,469,402                                            |   | $      | -                                    |   | $      | 240                                   |   | $      | 80,403                                                       |   | $      | (25,091                      | )      | $      | (3,890,920)                                                                            | )      | $      | 1,667,526               |   |

----

 

**BIO-BRIDGE      SCIENCE INC. AND SUBSIDIARIES**

**(A      DEVELOPMENT STAGE COMPANY)**

**UNAUDITED      CONDENSED CONSOLIDATED STATEMENTS OF CHANGES**

**IN      SHAREHOLDERS’ EQUITY AND COMPREHENSIVE GAIN (LOSS) FOR THE PERIOD FROM FEBRUARY      11, 2002**

**(INCEPTION)      THROUGH SEPTEMBER 30, 2007 (Continued)**

|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      | Preferred                |    |          |   |          |      |                           |   |       |   |                              |    |   |   |
|--------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------|------------|------------------------------------|--------|------------------------------|--------|---------|-----------|--------------------------|---------|---------------|--------|---------------|-----------|--------------------------------|--------|------------|--------|-----------------------------------|---------|--------|--------|
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      | Stock                    |    |          |   |          |      |                           |   |       |   |                      Deficit |    |   |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      | Dividend                 |    |          |   | Common        |      | Accumulated                    |   |       |   | Accumulated                       |    |   |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      | Payable                  |    | Additional    |   | Stock         |      | Other                          |   |       |   | During                    the     |    |   |   |
|                                                                                                                                             |   | Common                    Stock |       | Preferred                    Stock |   | in                    common |   | Paid-in |      | To                    be |    | Comprehensive |   | Subscriptions |      | Development                    |   |       |   |
|                                                                                                                                             |   | Shares                          |       | Amount                             |   | Shares                       |   | Amount  |      | Shares                   |    | Capital       |   | Issued        |      | Gain                    (Loss) |   | Receivable |   | Stage                             |    | Total  |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      |                     |    |          |   |          |      |                           |   |       |   |                              |    |   |   |
| **BALANCE                    DECEMBER 31, 2006**                                                                                                 |   |                            | 33,492,001 |                               | $      | 33,492                       |   |    | -         |                     | $       | -             |   | $             | -         |                           | $      | 5,469,402  |   | $                                 | 240     |   | $      | 80,403 |   | $ | (25,091 | ) | $ | (3,890,920 | ) | $ | 1,667,526 |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      |                     |    |          |   |          |      |                           |   |       |   |                              |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance                    of common shares at $0.75 per share for cash, net of Issuance                    costs                               |   |                            | -     |                               |   | -                       |   |    | -    |                     |    | -        |   |          | -    |                           |   | 222,203    |   |                              | 297     |   |   | -  |   |   | (200,000) |   |   | -  |   |   | 22,500 |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      |                     |    |          |   |          |      |                           |   |       |   |                              |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance                    of preferred shares at $0.75 per share for cash, net of issuance                    costs                            |   |                            | -          |                               |   | -                            |   |    | 4,000,000 |                     |    | 4,000         |   |          | -         |                           |   | 2,996,000  |   |                              | -       |   |   | - |   |   | - |   |   | - |   |   | 3,000,000 |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      |                     |    |          |   |          |      |                           |   |       |   |                              |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Deemed                    dividend related to beneficial conversion feature of convertible                    preferred                    stock |   |                            | -          |                               |   | -                            |   |    | -         |                     |    | -             |   |          | -         |                           |   | 1,293,320  |   |                              | -       |   |   | - |   |   | - |   |   | (1,293,320 | ) |   | - |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      |                     |    |          |   |          |      |                           |   |       |   |                              |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Accrual                    of preferred stock dividend                                                                                           |   |                            | -          |                               |   | -                            |   |    | -         |                     |    | -             |   |          | 227,000   |                           |   | -          |   |                              | -       |   |   | - |   |   | - |   |   | (227,000 | ) |   | - |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      |                     |    |          |   |          |      |                           |   |       |   |                              |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Payment                    of preferred stock                    dividend                                                                        |   |                            | -          |                               |   | -                            |   |    | -         |                     |    | -             |   |          | (180,000) |                           |   | 179,820    |   |                              | 180     |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      |                     |    |          |   |          |      |                           |   |       |   |                              |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Compensatory                    shares issued to consultant                                                                                      |   |                            | 30,000     |                               |   | 30                           |   |    | -         |                     |    | -             |   |          | -         |                           |   | 67,694     |   |                              | 20      |   |   | - |   |   | - |   |   | - |   |   | 67,744 |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      |                     |    |          |   |          |      |                           |   |       |   |                              |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Employee                    stock options                                                                                                        |   |                            | -          |                               |   | -                            |   |    | -         |                     |    | -             |   |          | -         |                           |   | 129,773    |   |                              | -       |   |   | - |   |   | - |   |   | - |   |   | 129,773 |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      |                     |    |          |   |          |      |                           |   |       |   |                              |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Consultant                    stock option                                                                                                       |   |                            | -          |                               |   | -                            |   |    | -         |                     |    | -             |   |          | -         |                           |   | 147,190    |   |                              | -       |   |   | - |   |   | - |   |   | - |   |   | 147,190 |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      |                     |    |          |   |          |      |                           |   |       |   |                              |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance                    of shares for previously exercised stock option                                                                      |   |                            | 240,000    |                               |   | 240                          |   |    | -         |                     |    | -             |   |          | -         |                           |   | -          |   |                              | (240    | )      |   | - |   |   | - |   |   | - |   |   | - |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      |                     |    |          |   |          |      |                           |   |       |   |                              |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Proceeds                    from previously                    issued stock                                                                      |   |                            | -     |                               |   | -                       |   |    | -    |                     |    | -        |   |          | -    |                           |   | -     |   |                              | -  |   |   | -  |   |   | 25,071 |   |   | -  |   |   | 25,071 |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      |                     |    |          |   |          |      |                           |   |       |   |                              |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Exercise                    of options                                                                                                           |   |                            | 415,675    |                               |   | 416                          |   |    | -         |                     |    | -             |   |          | -         |                           |   | -          |   |                              | -       |   |   | -  |   |   | - |   |   | - |   |   | 416 |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      |                     |    |          |   |          |      |                           |   |       |   |                              |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign                    currency translation loss                                                                                             |   |                            | -          |                               |   | -                            |   |    | -         |                     |    | -             |   |          | -         |                           |   | -          |   |                              | -       |   |   | 79,168 |   |   | - |   |   | - |   |   | 79,168 |   |
|                                                                                                                                             |   |                            |       |                               |   |                         |   |    |      |                     |    |          |   |          |      |                           |   |       |   |                              |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net                    loss                                                                                                                      |   |                            | -          |                               |   | -                            |   |    | -         |                     |    | -             |   |          | -         |                           |   | -          |   |                              | -       |   |   | - |   |   | - |   |   | (1,186,308 | ) |   | (1,186,308 | ) |
| **BALANCE                    September 30, 2007****(unaudited)**                                                                                 |   |                            | 34,177,676 |                               | $      | 34,178                       |   |    | 4,000,000 |                     |  $ | 4,000         |   | $             | 47,000    |                           | $      | 10,505,402 |   | $                                 | 497     |   | $      | 159,571 |   | $ | (200,020 | ) | $ | (6,597,548 | ) | $ | 3,953,080 |   |

----

 

**BIO-BRIDGE      SCIENCE INC. AND SUBSIDIARIES**

**(A      DEVELOPMENT STAGE COMPANY)**

**UNAUDITED      CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

|                                                                                                      |   | **For                nine months****Ended September 30,                2007** |       | **For                nine months Ended September30, 2006** |   | **For                the Period****From                February****11,                2002****(Inception)****Through                September 30,****2007** |   |
|-----------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------------------------|------------|-----------------------------------------------------------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| **CASH                FLOWS FROM OPERATING ACTIVITIES**                                                   |   |                                                                                    |       |                                                            |   |                                                                                                                                                        |   |
| Net                loss                                                                                   |   | $                                                                                       | (1,186,308 | )                                                               | $      | (1,052,984                                                                                                                                                  | )      | $ | (5,077,228 | ) |
| Adjustments                to reconcile net loss to net cash used in operating                activities: |   |                                                                                    |       |                                                            |   |                                                                                                                                                        |   |   |   |   |
| Depreciation                                                                                              |   |                                                                                    | 14,249     |                                                            |   | 5,055                                                                                                                                                       |   |   | 39,136 |   |
| Amortization                of land use right                                                             |   |                                                                                    | 12,790     |                                                            |   | 12,262                                                                                                                                                      |   |   | 68,829 |   |
| Non                cash stock compensation expense                                                        |   |                                                                                    | 344,707    |                                                            |   | 364,659                                                                                                                                                     |   |   | 1,603,838 |   |
| Unrealized                loss on trading securities                                                      |   |                                                                                    | 227,930    |                                                            |   | -                                                                                                                                                           |   |   | 227,930 |   |
| Loss                on sale of investment                                                                 |   |                                                                                    | -          |                                                            |   | -                                                                                                                                                           |   |   | 2,107 |   |
| Decrease                (increase) in prepaid expense and other assets                                    |   |                                                                                    | (3,455)    |                                                            |   | (7,137                                                                                                                                                      | )      |   | (20,283 | ) |
| (Decrease)                increase in payable to contractor                                               |   |                                                                                    | (353,973   | )                                                               |   | -                                                                                                                                                           |   |   | 120,613 |   |
| (Decrease)                increase in accrued expenses and other payable                                  |   |                                                                                    | (4,295     | )                                                               |   | 54,237                                                                                                                                                      |   |   | 151,149 |   |
| Net                Cash Used In Operating Activities                                                      |   |                                                                                    | (948,355   | )                                                               |   | (623,908                                                                                                                                                    | )      |   | (2,883,909 | ) |
|                                                                                                      |   |                                                                                    |       |                                                            |   |                                                                                                                                                        |   |   |   |   |
| **CASH                FLOWS FROM INVESTING ACTIVITIES**                                                   |   |                                                                                    |       |                                                            |   |                                                                                                                                                        |   |   |   |   |
| Purchase                of land use right                                                                 |   |                                                                                    | -          |                                                            |   | -                                                                                                                                                           |   |   | (394,559 | ) |
| Increase                in construction in progress                                                       |   |                                                                                    | (16,984    | )                                                               |   | (267,908                                                                                                                                                    | )      |   | (1,691,089 | ) |
| Purchase                of fixed assets                                                                   |   |                                                                                    | (1,890     | )                                                               |   | (59,082                                                                                                                                                     | )      |   | (103,530 | ) |
| Purchase                of investment                                                                     |   |                                                                                    | -          |                                                            |   | -                                                                                                                                                           |   |   | (40,000 | ) |
| Purchase                of marketable securities                                                          |   |                                                                                    | (1,897,184 | )                                                               |   | -                                                                                                                                                           |   |   | (1,897,184 | ) |
| Net                Cash Used In Investing Activities                                                      |   |                                                                                    | (1,916,058 | )                                                               |   | (326,990                                                                                                                                                    | )      |   | (4,126,362 | ) |
|                                                                                                      |   |                                                                                    |       |                                                            |   |                                                                                                                                                        |   |   |   |   |
| **CASH                FLOWS FROM FINANCING ACTIVITIES**                                                   |   |                                                                                    |       |                                                            |   |                                                                                                                                                        |   |   |   |   |
| Proceeds                from issuance of common stock                                                     |   |                                                                                    | 47,571     |                                                            |   | 768,376                                                                                                                                                     |   |   | 4,266,233 |   |
| Proceeds                from issuance of preferred stock                                                  |   |                                                                                    | 3,000,000  |                                                            |   | -                                                                                                                                                           |   |   | 3,000,000 |   |
| Proceeds                from exercise of stock option                                                     |   |                                                                                    | 416        |                                                            |   | -                                                                                                                                                           |   |   | 994 |   |
| Repayment                to shareholders                                                                  |   |                                                                                    | (18,885)   |                                                            |   | -                                                                                                                                                           |   |   | - |   |
| Net                Cash Provided By Financing Activities                                                  |   |                                                                                    | 3,029,102  |                                                            |   | 768,376                                                                                                                                                     |   |   | 7,267,227 |   |
|                                                                                                      |   |                                                                                    |       |                                                            |   |                                                                                                                                                        |   |   |   |   |
| **NET                INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS**                                   |   |                                                                                    | 164,689    |                                                            |   | (182,522                                                                                                                                                    | )      |   | 256,956 |   |
|                                                                                                      |   |                                                                                    |       |                                                            |   |                                                                                                                                                        |   |   |   |   |
| Effect                of exchange rate changes on cash                                                    |   |                                                                                    | (4,053)    |                                                            |   | 28,845                                                                                                                                                      |   |   | 53,293 |   |
| Cash                and cash equivalents, beginning of period                                             |   |                                                                                    | 149,613    |                                                            |   | 385,646                                                                                                                                                     |   |   | - |   |
|                                                                                                      |   |                                                                                    |       |                                                            |   |                                                                                                                                                        |   |   |   |   |
| **CASH                AND CASH EQUIVALENTS, END OF PERIOD**                                               |   | $                                                                                       | 310,249    |                                                            | $      | 231,969                                                                                                                                                     |   | $ | 310,249 |   |
|                                                                                                      |   |                                                                                    |       |                                                            |   |                                                                                                                                                        |   |   |   |   |
| **SUPPLEMENTAL                CASH FLOW INFORMATION**                                                     |   |                                                                                    |       |                                                            |   |                                                                                                                                                        |   |   |   |   |
| Interest                Paid                                                                              |   | $                                                                                       | -          |                                                            | $      | -                                                                                                                                                           |   | $ | - |   |
| Income                taxes Paid                                                                          |   | $                                                                                       | -          |                                                            | $      | -                                                                                                                                                           |   | $ | - |   |
| **SUPPLEMENTAL                NON-CASH INVESTING AND FINANCING ACTIVITIES**                               |   |                                                                                    |       |                                                            |   |                                                                                                                                                        |   |   |   |   |
| Deemed                preferred stock dividend                                                            | $      |                                                                                    | 1,293,320  |                                                            | $      | -                                                                                                                                                           |   | $ | 1,293,320 |   |
| Preferred                stock dividend                                                                   | $      |                                                                                    | 227,000    |                                                            | $      | -                                                                                                                                                           |   | $ | 227,000 |   |

----

**BIO-BRIDGE      SCIENCE, INC. AND SUBSIDIARIES**

**NOTES      TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL**

**STATEMENTS      AS OF SEPTEMBER 30, 2007**

**NOTE      1 - BASIS OF PRESENTATION**

**NOTE      2 - ORGANIZATION AND PRINCIPAL ACTIVITIES**

History      of losses and negative cash flows

----

**NOTE      3-SUMMARY OF PRINCIPAL ACCOUNTING POLICIES**

The      Company’s trading      securities are carried at fair value with changes in fair value recognized      in      the current period condensed consolidated statements of operations. Gains or      losses realized upon sale of all securities are recognized in other income      or      expense at the time of sale.

|                                                      |   | 2007   |   | 2006   |   |
|-----------------------------------------------------------|--------|--------|--------|--------|--------|
| Quarter                / Year end RMB : US$ exchange rate |   |   | 7.5108 |   |   | 7.8087 |   |
| Average                yearly RMB : US$ exchange rate     |   |   | 7.6598 |   |   | 7.9395 |   |

----

 

----

EITF      No.      96-18, “Accounting for Equity Instruments that are Issued to Other than      Employees for Acquiring, or in Conjunction with Selling, Goods or Services”(EITF 96-18) for our non-employee stock-based awards. Under EITF 96-18, the      measurement date at which the fair value of the stock-based award is measured      is      equal to the earlier of 1) the date at which a commitment for performance by      the      counterparty to earn the equity instrument is reached or 2) the date at which      the counterparty’s performance is complete. We recognize stock-based      compensation expense for the fair value of the vested portion of non-employee      awards in our consolidated statements of operations.

*Accounting      for Registration Payment Arrangements*
*Accounting      for Contingencies*

* *

**NOTE 4      - SHAREHOLDER'S EQUITY**

----

**ISSUANCE      OF 4,000,000 PERFERRED SHARES AT $ 0.75 PER SHARE FOR TOTAL CONSIDERATION OF      $3,000,000**

certain      anti-dilution protection.      The      warrants are exercisable through January 30, 2010 into 3,000,000 shares of      the      Company’s common stock for $1.00 per share.

**ISSUANCE      OF COMMON STOCK FOR CASH**

----

**ISSUANCE      OF COMMON STOCK FOR SERVICES**

On      March      6, 2006, we engaged CH Capital LLC for financial consulting services and agreed      to issue a total of 50,000 shares of common stock for these financial consulting      services. 25,000 shares were issued on March 6, 2006 and an additional 25,000      shares were issued on September 6, 2006. The fair value of the 50,000 shares      was      $101,250 and was determined as follows: the value of the first 25,000 shares      was      calculated using the closing share price of $1.80 on March 6, 2006 and the      value      of the remaining 25,000 shares was calculated using the closing share price of      $2.25 on September 6, 2006. The Company recorded $83,506 as compensation cost      in      2006 and $17,744 as compensation cost in 2007.

**ISSUANCE      OF STOCK OPTIONS AND WARRANTS**

----

On      October 14, 2005, the Company issued to Mr. Liang Qiao, MD, the Company's chief      executive officer, an option to purchase 600,000 shares of common stock at      $0.55      per share to be exercised with a ten-year (10) period. The options granted      were      valued at $157,770 at the date of grant, which was determined by the      Black-Scholes valuation method, using the following assumptions: no expected      dividend yield; risk-free interest rates of 3.4%; expected lives of four years;      and estimated volatility of 70 percent based on recent history of the stock      price in the industry. The value of the options will be amortized over the      three      year vesting period. For quarter ended September 30, 2007, $13,150 has been      amortized and included in the accompanying statement of operations.

----

**EXERCISE      OF STOCK OPTIONS**

**INVESTMENT      AGREEMENT**

On      November 29, 2005, the Company and Dutchess entered into a Registration Rights      Agreement. Pursuant to the Registration Rights Agreement, the Company is      required to file a registration statement within 30 days for purposes of      registering the resale of 2,000,000 shares of common stock to be issued under      the terms of the Agreement. Other than in respect of this transaction, there      are      no material relationships between the Company and Dutchess, or their respective      affiliates.

**NOTE      5-STOCK OPTION PLAN**

|                                             |   | Options                Granted |      | Weighted                AverageExercise                Price |   |
|--------------------------------------------------|--------|--------------------------------|-----------|--------------------------------------------------------------|--------|
|                                             |   |                           |      |                                                         |   |   |   |
| Outstanding                at January 1, 2007    |   |                           | 2,685,675 |                                                         | $      | 0.37 |   |
|                                             |   |                           |      |                                                         |   |   |   |
| Granted                                          |   |                           | 120,000   |                                                         |   | 0.001 |   |
| Exercised                                        |   |                           | (415,675  | )                                                            | $      | 0.001 |   |
| Withdrawn                                        |   |                           | (25,000   | )                                                            | $      | 0.001 |   |
|                                             |   |                           |      |                                                         |   |   |   |
| Outstanding                at September 30, 2007 |   |                           | 2,365,000 |                                                         | $      | 0.41 |   |
|                                             |   |                           |      |                                                         |   |   |   |
| Exercisable                at September 30, 2007 |   |                           | 1,733,333 |                                                         | $      | 0.38 |   |

----

 

|                                   |   | Options                Outstanding |      | Options                Exercisable                           |   |
|----------------------------------------|--------|------------------------------------|-----------|--------------------------------------------------------------|--------|
| Range                of ExercisePrices |   | Number                of Shares    |      | Weighted                AverageExercise                Price |   | Weighted                AverageRemaining                ContractualLife                (in years) |   | Number                of Shares |   | Weighted                Average Exercise Price |   |
|                                   |   |                               |      |                                                         |   |   |   |   |   |   |   |
| $0.001                to $0.55         |   |                               | 2,365,000 |                                                         | $      | 0.41 |   |   |  |   |   | 1 |   |   | 1,733,333 |   | $ | 0.38 |   |
|                                   |   |                               | 2,365,000 |                                                         |   |  |   |   |  |   |   |  |   |   | 1,733,333 |   |   |  |   |

 

|                                           |   | Number                of Shares |      |
|------------------------------------------------|--------|---------------------------------|-----------|
|                                           |   |                            |      |
| Nonvested                at January 1, 2007    |   |                            | 1,120,000 |   |
| Granted                                        |   |                            | -         |   |
| Vested                                         |   |                            | (479,166  | ) |
| Withdrawn                                      |   |                            | (9,167    | ) |
| Nonvested                at September 30, 2007 |   |                            | 631,667   |   |

**NOTE 6      - COMMITMENTS AND CONTINGENCIES**

----

**NOTE 6      - SUBSEQUENT EVENT**

----

**Item      2. Management's Discussion and Analysis or Plan of      Operation**

| ·   | our                ability to finance our activities and maintain our financial                liquidity; |
|--------------------|-----------------------------------------------------------------------------------------------------------|
| ·   | our                ability to attract and retain qualified, knowledgeable                employees; |
|--------------------|-----------------------------------------------------------------------------------------------------|
| ·   | our                ability to complete product development; |
|--------------------|-------------------------------------------------------------|
| ·   | our                ability to obtain regulatory approvals to conduct clinical                trials; |
|--------------------|------------------------------------------------------------------------------------------------------|
| ·   | our                ability to design and market new products                successfully; |
|--------------------|-------------------------------------------------------------------------------------------|
| ·   | our                failure to acquire new customers in the                future; |
|--------------------|-----------------------------------------------------------------------------------|
| ·   | deterioration                of business and economic conditions in our                markets; |
|--------------------|-------------------------------------------------------------------------------------------------|
| ·   | intensely                competitive industry conditions. |
|--------------------|-----------------------------------------------------------|

**OVERVIEW**

**Plan      of Operation**

We      plan      to develop three more products in the near future to diversify our potential      product offerings, and these new potential products are summarized as      follows:

| ·  | HPV                preventive and therapeutic vaccines - an oral vaccine that will be                used to                prevent and treat HPV6, 11, 16, 18, 31, 45, and 58 infection (cover                >90% of HPV causing cervical                cancer). |
|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·  | Colon                cancer therapeutic vaccine--an oral vaccine that treats CEA+ colon                cancer. |
|--------------|----------------------------------------------------------------------------------------------------------------|

| ·  | Mucosal                adjuvant -- an adjuvant that can be used to enhance vaccines efficacy                in                elderly, e.g. for influenza virus vaccine for age over                60. |
|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ·  | approximately                $0.7 million for our laboratory/bio-manufacturing facility’s steam and                electricity work for Phase I laboratory manufacturing facility project                in                Beijing, China; |
|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·  | approximately                $1.0 million to purchase advanced laboratory equipment and supplies                for                our vaccine production; |
|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·  | approximately                $0.5 million for Phase I clinical study and the preparatory                work; |
|--------------|---------------------------------------------------------------------------------------------------------------|

| ·  | approximately                $0.8 million for working capital and general corporate needs;                and |
|--------------|---------------------------------------------------------------------------------------------------------------|

| ·  | approximately                $0.6 million for pre-clinical trials on HPV vaccines, colon cancer                vaccine, and mucosal adjuvant. |
|--------------|-----------------------------------------------------------------------------------------------------------------------------------------------|

We      signed      an exclusive agency agreement with Xinhua Surgical Instruments Co. Ltd. to      distribute its operational instruments in the United States at the end of 2005.      We are currently forming a sales team and seeking collaboration with local      distributors and developing markets for Xinhua instruments. As these activities      will take significant amount of time, we do not expect to generate any      significant revenues in the next 12 months.

**Results      of Operations**

**Three-month      period ended September 30, 2007 and September 30, 2006**

----

**Nine-      month period ended September 30, 2007 and September 30,      2006**

**Liquidity      and Capital Resources**

**Critical      Accounting Policies**

----

*Accounting      for Registration Payment Arrangements*
*Accounting      for Contingencies*

**Recent      Accounting Pronouncements**

----

* *

**Lease      Commitment**

**Royalty      and License Arrangements**

 

**Contractual      Obligations**

|                                   |   |                  Payments due by period ($ in thousands) |   |
|----------------------------------------|--------|---------------------------------------------------------------|--------|
| Contractual                Obligations |   | Total                                                         |   | Less                than 1year |   | 1                to 3 years |   |
|                                   |   |                                                          |   |   |   |   |   |
| Lease                obligation        |   |                                                          | 96     |   |   | 12 |   |   | 84 |   |
|                                   |   |                                                          |        |   |   |  |   |   |  |   |
| Total                                  |   | $                                                             | 96     |   | $ | 12 |   | $ | 84 |   |

 

**Item      3. Controls and Procedures**

 

**PART      II - OTHER INFORMATION**

**Item      1. Legal Proceedings**

----

**Item      2. Unregistered Sales of Equity Securities and Use of      Proceeds**

**Item      3. Defaults Upon Senior Securities**

**Item      4. Submission of Matters to a Vote of Security Holders**

**Item      5. Other Information**

**Item      6. Exhibits**

 

**SIGNATURES**

**Bio-Bridge      Science, Inc.**

|   |                                     |   |                                      |   |
|--------|------------------------------------------|--------|-------------------------------------------|--------|
|   | */s/                Dr. Liang Qiao*      |   |                                      |   |
|   | *By:                Dr. Liang Qiao*      |   | *Dated:                November 14, 2007* |   |
|   | *Chief                Executive Officer* |   |                                      |   |

----

**EXHIBIT      INDEX**

 

| 3.1(i)*    |   | Certificate                of incorporation of the registrant, as currently in                effect             |
|------------|--------|------------------------------------------------------------------------------------------------------------------|
|       |   |                                                                                                             |
| 3.1(ii)*   |   | Bylaws                of the registrant, as currently in effect                                                  |
|       |   |                                                                                                             |
| 3.1(iii)** |   | Certificate                of Designation of Series A Preferred Stock                                            |
|       |   |                                                                                                             |
| 4.1**      |   | Form                of Common Stock Warrant Agreement dated January 2007                                         |
|       |   |                                                                                                             |
| 4.2**      |   | Registration                Rights Agreement dated January 2007                                                  |
|       |   |                                                                                                             |
| 10.1**     |   | Securities                Purchase Agreement dated January 2007                                                  |
|       |   |                                                                                                             |
| 31.1       |   | Certification                of Chief Executive Officer                                                          |
|       |   |                                                                                                             |
| 31.2       |   | Certification                of Chief Financial Officer                                                          |
|       |   |                                                                                                             |
| 32.1       |   | Section                1350 Certifications of Chief Executive Officer and Chief Financial                Officer |

----